COMMUNIQUÉS West-GlobeNewswire

Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
26/10/2026
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports ART26.12’s potential as a [...]
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
26/10/2026
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on [...]
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
26/10/2026
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors Anticipate reporting initial Phase 1 data in the fourth quarter of 2027 Plan to present a [...]
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
26/10/2026
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision [...]
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
26/10/2026
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
26/10/2026
Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (Nasdaq: DAVI) (" [...]
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
26/10/2026
Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of 25% and a DCR of 44% Safety profile was manageable; further dose [...]
Kraig Biocraft Laboratories Launches Performance Yarn Development Program and Ships Spider Silk to Yarn and Aerospace Innovator
26/10/2026
Initiative Builds on First Commercial Yarn Shipment to Create New Constructions and Blends for the Next Generation of Fabrics and Apparel ANN ARBOR, Mich., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, [...]
Serapha Bio Announces Positive Interim Safety and Efficacy Data from the SERP-01 Investigator-Initiated Trial Presented at the ERS Alpha-1 Antitrypsin Conference 2026
26/10/2026
Single administration of SERP-01 was associated with increases in total serum AAT above the protective threshold with durable correction out to 10 months Elastase inhibition assay results showed serum approached [...]
Changes in Orion Group’s Executive Team as of 1 January 2027
26/10/2026
ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group’s Executive Team as of 1 January 2027 To accelerate the implementation of its strategy and [...]
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
26/10/2026
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 [...]
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
26/10/2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third [...]
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
26/10/2026
BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that [...]
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
26/10/2026
Four of nine evaluable patients responded to TILT-123 combined with pembrolizumab and pegylated liposomal doxorubicin, including two complete responses HELSINKI, Finland, Oct. 26, 2026 (GLOBE NEWSWIRE) -- TILT [...]
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
26/10/2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated [...]
VETmAb Biosciences Announces Positive Clinical Proof-of-Concept Results for Long-Acting Anti-IL-23 Antibody in Canine Chronic Inflammatory Enteropathy
26/10/2026
In the VMB-C001a group, 77.8% of dogs were considered a treatment success, compared with 30.0% in the placebo group VMB-C001a granted eligibility for the U.S. Food and Drug Administration’s (FDA) Center for Veterinary [...]
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
26/10/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD ® ) [...]
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
26/10/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 10, 2026 NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
26/10/2026
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence [...]

Pages